Ciclopirox

證據等級: L5

預測適應症: 0 個

Ciclopirox: No TxGNN Prediction Available — Insufficient Data for Repurposing Assessment

One-Sentence Summary

Ciclopirox (DrugBank: DB01188) is a broad-spectrum antifungal agent primarily used topically for dermatomycoses and onychomycosis. No TxGNN repurposing prediction is available for this candidate in the current Evidence Pack, as the predicted_indications array is empty. Without a model-generated target indication or supporting evidence, a full repurposing evaluation cannot be completed at this stage.

Quick Overview

Item	Content
Original Indication	Fungal skin and nail infections (dermatomycoses, onychomycosis) — based on general pharmacological knowledge; no TFDA/SmPC data loaded
Predicted New Indication	Not available — no TxGNN prediction generated
TxGNN Prediction Score	Not available
Evidence Level	L5 (no supporting studies identified in this pack)
Denmark Market Status	Not marketed (no authorisations registered with Laegemiddelstyrelsen)
Number of Marketing Authorisations	0
Recommended Decision	Hold

Why No Prediction Is Available

The Evidence Pack for this candidate (TW-DB01188-multi, v4) was generated with two confirmed data gaps that together prevent a complete analysis:

Missing mechanism of action (MOA) data — DrugBank query returned a record (query ID 2, status: success), but MOA was not extracted into the pack. Ciclopirox is known to act by chelating polyvalent metal cations (Fe³⁺, Al³⁺) that are essential cofactors for fungal cytochrome-dependent enzymes, thereby disrupting DNA repair, cell respiration, and cell division. However, this information has not been formally validated and loaded into the pipeline.
No TFDA/regulatory label data — The TFDA Summary of Product Characteristics (SmPC), including approved indications and contraindications, was not retrieved (data gap DG001, severity: Blocking). This is a prerequisite for the Safety Stage 1 screening.

Without these two inputs, the TxGNN knowledge-graph matching and disease-mapping steps could not produce a ranked prediction list, resulting in an empty predicted_indications field.

Denmark Market Information

Ciclopirox currently holds no marketing authorisations with the Danish Medicines Agency (Laegemiddelstyrelsen) and is not listed as a marketed product in Denmark. Neither a national authorisation nor a centralised EMA authorisation has been identified for this substance.

Note: Ciclopirox is marketed in several other EU/EEA countries (e.g., Germany, France) under brand names such as Batrafen and Mycoster, primarily as topical formulations (cream, solution, nail lacquer). A centralised or mutual-recognition procedure application may be a pathway if a Danish indication is pursued.

Safety Considerations

Both key warnings and contraindications were listed as data gaps in this Evidence Pack. No drug–drug interaction records were found in the DDI query (query ID 1, status: not_found).

Please refer to the approved Summary of Product Characteristics (SmPC) — available from the EMA product database or national agencies where ciclopirox is authorised — for full safety information including contraindications, warnings, and drug interactions.

Conclusion and Next Steps

Decision: Hold

Rationale: The Evidence Pack is structurally incomplete — both the TxGNN predicted indication and the regulatory safety data are missing, making it impossible to assess repurposing feasibility or safety profile at this stage.

To proceed, the following is needed:

Retrieve TFDA SmPC / EMA SmPC: Download and parse the approved product label to extract indications, contraindications, and key warnings (resolves data gap DG001 — Blocking)
Load MOA from DrugBank API: The DrugBank query was successful (result_count: 1); re-run the extraction step to populate original_moa (resolves data gap DG002 — High)
Re-run TxGNN prediction pipeline: Once MOA and indication data are loaded, re-execute the knowledge-graph and deep-learning prediction steps to generate predicted_indications
Confirm Denmark regulatory pathway: Although ciclopirox is not currently marketed in Denmark, assess whether an existing EMA centralised authorisation or mutual-recognition procedure can serve as the basis for a Danish application
Re-generate Evidence Pack: After the above steps, generate a new pack (v5+) for full L1–L5 evidence assessment and final Go/Hold/Proceed with Guardrails decision
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.